Crystalline Psilocybin Polymorphs for Scalable Production
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing methods for producing psilocybin are limited in scale, purity, and consistency, making it challenging to produce large batches suitable for clinical trials and commercial use, particularly for the treatment of treatment-resistant depression.
Innovation Solution
Development of crystalline psilocybin in specific polymorphic forms, such as Polymorph A and Polymorph A', characterized by distinct XRPD and DSC patterns, ensuring high chemical purity and stability, with methods to reproduce these forms consistently.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If existing methods for producing psilocybin are used, then production can be achieved, but the scale is limited and cannot meet clinical trial and commercial requirements
Solution Approach 1:
The patent modifies reaction parameters including solvent selection (using ethyl methyl carbonate instead of traditional solvents), temperature control, and stoichiometry to enable scalable production while maintaining product purity and consistency across large batches
Solution Approach 2:
The synthesis process is divided into discrete, optimized stages with intermediate purification steps, allowing each segment to be independently controlled and scaled, facilitating transition from small-scale research to large-scale commercial production
2Manufacturing precision
If existing production methods are used, then psilocybin can be produced, but chemical purity and consistency are insufficient for medical use
Solution Approach 1:
The patent introduces specific intermediate compounds and purification intermediates that facilitate selective separation and purification of psilocybin from reaction mixtures, ensuring high chemical purity while maintaining manufacturing feasibility through established purification techniques
Solution Approach 2:
The patent replaces traditional mechanical filtration and separation methods with chemically-driven purification approaches including selective precipitation, crystallization from specific solvents, and chemical purification steps that achieve higher purity levels with simpler equipment
3Reliability
If existing production methods are used, then psilocybin can be produced, but batch-to-batch consistency is poor for clinical applications
Solution Approach 1:
The patent implements quality control measures including HPLC analysis, NMR spectroscopy, and other analytical methods at multiple stages of production to monitor and adjust parameters, ensuring batch-to-batch consistency and reproducibility required for clinical trial materials
Solution Approach 2:
The patent establishes predefined protocols for reagent preparation, reaction conditions, and purification parameters before production begins, along with selection of specific polymorphic forms with predetermined characteristics, ensuring consistent results across batches without requiring complex real-time adjustments
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Achieves chemically pure, stable, and consistent large-scale production of psilocybin, suitable for medical use, particularly in treating depression, with batch-to-batch consistency and reproducibility.
Implementation Method 1
Development of crystalline psilocybin in specific polymorphic forms, such as Polymorph A and Polymorph A', characterized by distinct XRPD and DSC patterns
Data Source
AI summary
This invention relates to the large-scale production of psilocybin for use in medicine. More particularly, it relates to a method of obtaining high purity crystalline psilocybin, particularly, in the form of Polymorph A. It further relates to a method for the manufacture of psilocybin and intermediates in the production thereof and formulations containing psilocybin.